Neumora Therapeutics, Inc. NMRA 深 滬
已收盤 01-09 16:00:00 美东时间
2.22
-0.110
-4.72%
華盛通- 最 高2.57
- 今 開2.36
- 成交量 215.87万股
- 最 低 2.21
- 昨 收 2.33
- 總市值 3.60亿
- 52周最高 3.25
- 市盈率 靜 --
- 換手率 1.33%
- 52周最低 0.611
- 委 比 -74.84%
- 總股本 1.62亿
- 歷史最高 21.00
- 量 比 0.39
- 振 幅 15.45%
- 歷史最低 0.611
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | 脑机接口概念持续强势！脑再生科技大涨超60%；Revolution涨超28.6%
脑机接口概念持续强势！脑再生科技大涨超60%，近四日涨幅超150%；“收购传闻”引股价过山车，Revolution隔夜涨超28.6%，盘后跌超6%>>
01-08 15:53
Neumora's Alzheimer's Agitation Drug Shows Early Promise
NMRA-511 showed promising results in Phase 1b study for Alzheimer's disease agitation with favorable tolerability and safety profile.
01-06 00:11
Neumora Therapeutics Reports Results From NMRA-511 Phase 1b Signal-Seeking Study In People With Alzheimer's Disease Agitation
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population
01-05 19:31
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Shares of ZIM Integrated Shipping Services Ltd (NYSE:ZIM) rose sharply in pre-m...
2025-12-23 18:16
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.
2025-12-02 02:45
RBC Capital Upgrades Neumora Therapeutics to Outperform, Raises Price Target to $7
RBC Capital analyst Brian Abrahams upgrades Neumora Therapeutics (NASDAQ:NMRA) from Sector Perform to Outperform and raises the price target from $4 to $7.
2025-12-01 19:33
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Stifel Maintains Hold on Neumora Therapeutics, Raises Price Target to $3
Stifel analyst Paul Matteis maintains Neumora Therapeutics (NASDAQ:NMRA) with a Hold and raises the price target from $2 to $3.
2025-11-17 21:52
Neumora Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
Neumora Therapeutics shares are trading lower after the company reported worse-...
2025-11-06 21:55
